BlossomHill Therapeutics, Inc. BLSM PHARMA
Company Overview
BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndrome (HR-MDS). BlossomHill Therapeutics, Inc. was incorporated in 2020 and is based in San Diego, California.
Why Investors Should Care
Generates a return on equity of 46.0%, reflecting efficient use of shareholder capital.
Carries low leverage with a debt-to-equity ratio of 0.28.
Recent Developments
- 5-Year Trend Long-term compounding — profit CAGR -97.3%.
Growth & Price Performance
Compounded Profit Growth
| 5 Years: | -97.28% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -8.56% |
| 6 Months: | - |
| 3 Months: | - |
| 1 Month: | -28.53% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- RSI (14)37.52 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 46.0%.
CONS
- Earnings shrank at -97.3% CAGR over 5 years.
- Trading 45.5% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | BLSM BlossomHill Therapeutics, Inc. PHARMA | 14.63 | -3.11 | $465.01M | 0.00% | -43.41% | 45.97% | - | -97.28% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue | 0 | 0 |
| Cost of Revenue | - | - |
| Gross Profit | - | - |
| Operating Expenses | 11.45M | 22.11M |
| Operating Income | -11.45M | -22.11M |
| EBITDA | -11.37M | -21.98M |
| Interest Expense | - | - |
| Pretax Income | -10.48M | -21.01M |
| Tax Provision | - | - |
| Net Income | -10.48M | -21.01M |
| Diluted EPS | -0.36 | -0.72 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Revenue | 0 | 0 |
| Cost of Revenue | - | - |
| Gross Profit | - | - |
| Operating Expenses | 36.40M | 64.02M |
| Operating Income | -36.40M | -64.02M |
| EBITDA | -36.05M | -63.58M |
| Interest Expense | - | - |
| Pretax Income | -30.70M | -60.55M |
| Tax Provision | - | - |
| Net Income | -30.70M | -60.55M |
| Diluted EPS | -1.06 | -2.08 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Total Assets | 106.78M | 162.97M |
| Current Assets | 104.17M | 138.83M |
| Cash & Equivalents | 100.15M | 136.68M |
| Inventory | - | - |
| Receivables | - | - |
| Total Liabilities | 179.66M | 294.70M |
| Current Liabilities | 6.77M | 15.48M |
| Long Term Debt | - | - |
| Total Debt | 525.00K | 22.40M |
| Total Equity | -72.88M | -131.73M |
| Shares Outstanding | 29.08M | 29.08M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Operating Cash Flow | -31.42M | -46.92M |
| Investing Cash Flow | -92.00K | -1.07M |
| Financing Cash Flow | 17.56M | 84.53M |
| Capital Expenditure | -92.00K | -1.07M |
| Free Cash Flow | -31.51M | -47.99M |
| Net Change in Cash | -13.95M | 36.53M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Gross Margin % | - | - |
| Operating Margin % | - | - |
| Net Margin % | - | - |
| ROE % | 42.1% | 46.0% |
| ROCE % | -36.4% | -43.4% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for BLSM
BlossomHill Therapeutics, Inc. (NASDAQ:BLSM) Stock Has Average Target Price of $35.00 - MarketBeat
<a href="https://news.google.com/rss/articles/CBMi2wFBVV95cUxQYnFMSTR4c25BRHpQOUwzWlloakxuUHhxT0hNbVNWVmlGUE1ERmN6aWJ3MDZjUThtak5uUUFydVYzN0g5Q0J1eG4tTFhMR1YtYk5wMGM4aXdHZnQ3QzZNdEJ6TnR5UGdaenNYSnlZZFlTTGc2UjlSYlJFS3BRcVg2X2RDZ1M4RXFUU2dCVE…
Cancer drug developer BlossomHill slips post IPO (BLSM:NASDAQ) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMijwFBVV95cUxOMlNnNHRham1wXzJRTS15MGt2Ukhja0NOTmp0bjFMdjluYXM0WmNBTXZKNlVlS2ZGUjlsTlRVekhXWWFNOTFqc1EyUXdBcEdjN0dIYjJlZ2lXem41WXkzbHh5dGZQOFVKYlBvOFZSbXc1NngwejNXMTFjUEtTeTczbFpqV25vV3Q4dHhKa3…
BlossomHill Therapeutics Announces Pricing of Upsized $150 Million Initial Public Offering - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxPNUljSGVBSXloUzh2ZEg3QTlEdEF2eXFiS2dWY204Zl83b1BMbXB3ZzNlaTRoMEZaQWJyZWczTzI0aGNockY0ME90VTdDUjh4UExqWndaWEFyY05hVHdkVWxNUC1QZXNpajVUSHpRTklwcE9kbk43T1gyU0Y2UDAwcG44bjRFQlo0TUd2Z1…
A Quick Look at Today's Ratings for BlossomHill Therapeutics(BLSM.US), With a Forecast Between $28 to $35 - Moomoo
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxOU3lGVFlDU3BxeGp3VVFuWFJYd29CZWVvVU1VMFNHaDdZUzFpbWFzVHEtc2pOTXlQU19Gb2M4X2J5T2toei1sUklKU205ME92UHZfdG9jOVktYkNwOFFYWjhZR2VXdHlzY2pSVXE3emR6WkgzWnVFT0pXZlV4eVdpZkxxXzV1alEyQ3Z0RG…
BlossomHill Therapeutics (BLSM) Stock Price, News & Analysis - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiU0FVX3lxTE9nZDN0UGFjNkhidktEX0tockdockM1TGVCeWRqQi02V0x3U2hteDB4T1VrOXZqUTBFUG5MaENwODBySWp2ejl3c200YTJnaEhDZWow?oc=5" target="_blank">BlossomHill Therapeutics (BLSM) Stock Price, News & Ana…
BlossomHill Therapeutics shares fall in debut after IPO - Investing.com
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxNNjFFQWx5VjE5T05TakZfejh0RlUtODIwRzdBekNQa0tYUlBuMGRFdm00Q1BsNUlVUzItMGVFbFk4b2h3bkVtT0ZYX19JX2tJcVhvSTlYbVBYNGN4d2xqVEJxTXNwelhFaWs5aUNJZHBlQWI0NF9nSG9NX002dDRGTTdDaEdBbVZhWXE1bF…
BLSM — Frequently Asked Questions
What is the current share price of BlossomHill Therapeutics, Inc. (BLSM)?
As of 2026-10-23 16:27 PDT, BlossomHill Therapeutics, Inc. (BLSM) trades at $14.63 on NasdaqGS. Its 52-week range is $13.94 to $26.82.
What is the market capitalisation of BLSM?
BlossomHill Therapeutics, Inc. (BLSM) has a market capitalisation of $465.01M on NasdaqGS.
What is the P/E ratio of BLSM?
BLSM trades at a trailing price-to-earnings (P/E) ratio of -3.11. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is -0.28.
What is the return on equity (ROE) of BLSM?
BLSM has a return on equity (ROE) of 45.97%. Its return on capital employed (ROCE) is -43.41%.
Is BLSM a good stock to buy?
This page provides a data-driven analysis of BlossomHill Therapeutics, Inc. (BLSM), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.